Urethral obstruction

Summary

Urethral obstruction (MONDO:0001556) is a disease and 3 clinical trials. Top therapeutic interventions include gabapentin. A subtype of urethral disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	urethral obstruction
Mondo ID	MONDO:0001556
MeSH	D014524
DOID	DOID:12577
SNOMED CT	95588004
UMLS	C0041972
MedGen	12015
Is cancer (heuristic)	no

Also known as: urethral obstruction · urethral obstruction (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of urethral disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urethral disorder › urethral obstruction

Related subtypes (9): prolapse of urethra, urethral intrinsic sphincter deficiency, urethral syndrome, urethral false passage, urethral calculus, urethral gland abscess, urethritis, fibroepithelial polyp of urethra, urethra neoplasm

Subtypes (2): urethral stricture, urethral obstruction sequence

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03151746	PHASE4	TERMINATED	Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion
NCT02315521	Not specified	RECRUITING	Standardized Prenatal Clinical Care for LUTO
NCT02446184	Not specified	TERMINATED	Fetal Cystoscopy for Lower Urinary Tract Obstruction

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
GABAPENTIN	4	1